Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.42 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | TYMS | P04818 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | PTAFR | P25105 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31620343 | 1.00 | PARP1 (0.42) | PARP1PARP10SRD5A1TYMSACHE | |
| SCHEMBL30856147 | 0.83 | TDP1 (0.49) | PARP1PARP10SRD5A1TYMSTDP1 | |
| SCHEMBL3267426 | 0.80 | F7 (0.42) | PARP1PARP10SRD5A1TYMSTDP1 | |
| SCHEMBL30856007 | 0.80 | F7 (0.42) | PARP1PARP10SRD5A1TYMSTDP1 | |
| SCHEMBL10531263 | 0.80 | PARP1 (0.46) | PARP1PARP10SRD5A1TYMSACHE | |
| SCHEMBL3273769 | 0.78 | PARP1 (0.44) | PARP1PARP10SRD5A1TYMSACHE | |
| SCHEMBL29615759 | 0.75 | CES1 (0.47) | PARP1PARP10SRD5A1TDP1L3MBTL1 | |
| SCHEMBL4268656 | 0.75 | CES1 (0.47) | PARP1PARP10SRD5A1TDP1L3MBTL1 | |
| SCHEMBL5518824 | 0.70 | PARP1 (0.58) | PARP1PARP10SRD5A1TYMSACHE | |
| SCHEMBL30855798 | 0.70 | SRD5A1 (0.45) | SRD5A1TYMSTDP1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| CN-101300244-A | Novel cercosporamide derivative | DAIICHI SANKYO CO LTD (JP) | 2008-11-05 | — | — | CN | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | PARP1 4384/4885PARP10 3583/4885SRD5A1 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.